Iridex to Report Fourth Quarter and Full Year 2020 Financial Results on March 22, 2021
Iridex Corporation (NASDAQ: IRIX) will release its financial results for Q4 and full year 2020 after trading on March 22, 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Iridex Corporation (NASDAQ: IRIX) will release its financial results for Q4 and full year 2020 after trading on March 22, 2021. A conference call with management is scheduled for 2:00 p.m. PT / 5:00 p.m. ET, which investors can access by calling (844) 707-0665 domestically or (703) 326-3030 internationally, using conference ID: 1137827. The event will also be webcast live and archived on Iridex's website. The company specializes in ophthalmic laser-based medical products for glaucoma and retinal diseases.
Details
News Market Reaction – IRIX
The recorded move for IRIX in the trading session of this news was +8.81%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MOUNTAIN VIEW, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the fourth quarter and full year of 2020 after the close of trading on Monday, March 22, 2021. The Company’s management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET.
Investors interested in listening to the conference call may do so by dialing (844) 707-0665 for domestic callers or (703) 326-3030 for international callers, using conference ID: 1137827. A live and archived webcast of the event will be available on the “Investors” section of the Company’s website at: www.iridex.com.
About Iridex
Iridex is a worldwide leader in developing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma, diabetic macular edema and other retinal diseases. Iridex products are sold in the United States and Germany through a direct sales force and in more than 100 countries through a network of independent distributors. For more information, visit www.iridex.com.
Investor Relations Contact:
Leigh Salvo
(415) 937-5404
investors@iridex.com
Media Contact:
Jamie Hall
Pascale Communications, LLC.
(724) 417-0167
pr@iridex.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.